Poly (ADP-ribose) polymerase inhibitors in cancer therapy [PDF]
Chinese Medical Journal. Poly(ADP-ribose) polymerase (PARP) inhibitors (PARPis) have emerged as critical agents for cancer therapy. By inhibiting the catalytic activity of PARP enzymes and trapping them in the DNA, PARPis disrupt DNA repair, ultimately leading to cell death ...
Ziqi Zhu, Yujun Shi, Jing Ni
doaj +4 more sources
Poly (ADP-ribose) polymerase inhibitors in the management of ovarian cancer [PDF]
Women's Health, 2018 There is considerable interest and enthusiasm within the clinical gynecologic oncology community regarding the potential for poly (ADP-ribose) polymerase inhibitors to play a critically relevant role in the management of epithelial ovarian cancer and ...
Maurie Markman
doaj +4 more sources
Update on poly(ADP-ribose) polymerase inhibitors resistance in ovarian cancer [PDF]
Frontiers in Pharmacology, 2023 Ovarian cancer is one of the most common reproductive system tumors. The incidence of ovarian cancer in China is on the rise. Poly(ADP-ribose) polymerase (PARP) inhibitor (PARPi) is a DNA repair enzyme associated with DNA damage repair.
Ruihong Dong +5 more
doaj +4 more sources
The potential for poly (ADP-ribose) polymerase inhibitors in cancer therapy [PDF]
Therapeutic Advances in Medical Oncology, 2011 The modulation of DNA repair pathways for therapeutic benefit in cancer has now become a reality with the development of poly (ADP-ribose) polymerase inhibitors (PARPi).
M. Javle, N. J. Curtin
doaj +5 more sources
Poly(ADP-Ribose)Polymerase (PARP) Inhibitors and Radiation Therapy [PDF]
Frontiers in Pharmacology, 2020 Poly(ADP-ribose)polymerase-1 (PARP1) is a DNA repair enzyme highly expressed in the nuclei of mammalian cells, with a structure and function that have attracted interest since its discovery.
Stephen A. Jannetti +10 more
doaj +3 more sources
Vascular Protection of Poly(ADP-ribose) Polymerase Inhibitors in the Combination Therapy With Vascular Endothelial Growth Factor Signaling Pathway Inhibitors [PDF]
Reviews in Cardiovascular MedicineThe Poly(ADP-ribose) polymerase (PARP) family comprises seventeen members that catalyze poly- or mono- adenosine diphosphate (ADP)-ribosylation, a pivotal post-translational modification regulating a wide array of cellular processes, including ...
Jie Ma +8 more
doaj +2 more sources
The Promise of Poly(ADP-Ribose) Polymerase (PARP) Inhibitors in Gliomas [PDF]
Journal of Immunotherapy and Precision Oncology, 2020 Diffuse infiltrating gliomas are a clinically and molecularly heterogeneous group of tumors that are uniformly incurable. Despite our growing knowledge of genomic and epigenomic alterations in gliomas, standard treatments have not changed in the past 2 ...
Nazanin Majd +3 more
doaj +4 more sources
The Poly(ADP-ribose) polymerase inhibitors in pancreatic cancer
Nowotwory, 2022 Genome instability and mutations are the hallmarks of cancer. Mutations within BRCA genes increase the risk of pancreatic cancer (PC) development. Poly(ADP-ribose) polymerase inhibitors (PARPi) show the synthetic lethality phenomenon in tumoral cells ...
Katarzyna Zubik +3 more
doaj +3 more sources
R2eGIN: Residual Reconstruction Enhanced Graph Isomorphism Network for Accurate Prediction of Poly (ADP–Ribose) Polymerase Inhibitors [PDF]
Bioinformatics and Biology InsightsAn advanced graph neural network (GNN) is of great promise to facilitate predicting Poly ADPribose polymerase inhibitors (PARPi). Recent studies design models by leveraging graph representations and molecular descriptor representations, unfortunately ...
Candra Zonyfar +3 more
doaj +2 more sources
Nanoparticle Formulations of Poly (ADP-ribose) Polymerase Inhibitors for Cancer Therapy [PDF]
Frontiers in Chemistry, 2020 A number of poly(ADP-ribose) polymerase (PARP) inhibitors have been recently approved for clinical use in BRCA mutated and other cancers. However, off-target toxicity of PARP inhibitors and the emergence of drug resistance following prolonged ...
Bijay Singh +10 more
doaj +2 more sources